Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.

…read more

Source: J&J pours another $20M into ViaCyte and sizes up its diabetes treatment


0 No comments